Skip to main content
. Author manuscript; available in PMC: 2021 Oct 30.
Published in final edited form as: Mol Psychiatry. 2020 Nov 10;26(8):4046–4054. doi: 10.1038/s41380-020-00941-x

Table 1.

The gender composition, age at study entry and end, number and interval between clinical observations and psychostimulant medication use for each symptom course group.

Symptom course groups
Never affected Improvers Stable Worsening Tests of group differences
Total number 129 110 63 60 -
Male
Female
79 (61%)
50 (39%)
81 (74%)
29 (26%)
44 (70%)
19 (30%)
42 (70%)
18 (30%)
χ2 =4.52
p = 0.21
Age at baseline: mean (SD) years 8.7 (3.0) 8.2 (2.0) 8.1 (2.4) 7.6 (2.8) F(3,358)=2.49, p=0.06
Age at last observation 13.3 (3.1) 13.8 (2.7) 12.6 (2.9) 12.0 (3.1) F(3,358)=6.75, p=0.0001 [Improvers=never affected]> [stable=worsening]
Clinical 2 assessments 3 4 or more 38 (30%) 25 (23%) 24 (38%) 19 (32%) χ2=6.64, p=0.36
29 (22%) 22 (20%) 13 (21%) 15 (25%)
62 (48%) 63 (57%) 26 (41%) 26 (43%)
Inter-observation interval Mean (SD) years 1.97 (0.9) 2.16 (1.22) 2.15 (1.08) 2.02 (0.97) F(3,358)=0.85, p=0.47
Baseline inattention 0.1 (0.5) 6.2 (2.2) 6.3 (2.9) 2.3 (2.5) F(3,358)=281, p<0.00001, Never affected <worsening <[stable=improvers]
Baseline hyperactivity-impulsivity 0.1 (0.4) 5.26 (2.7) 4.6 (2.1) 3.0 (3.1) F(3,358)=109, p<0.00001, Never affected <worsening <[stable=improvers]
Intelligence quotient 115 (16) 108 (13) 107 (16) 106 (15) F(3,358)=8.1, p<0.00001, Never affected >[worsening=stable=improvers]
Psychostimulant treatment during study
None Intermittent Constant NA 23 (24%) 19 (33%) 15 (33%) χ2=3.97, p=0.41
NA 54 (56%) 24 (41%) 22 (49%)
NA 19 (20%) 15 (26%) 8 (18%)